Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.

[Back to Overview]  [IACM Homepage]

TitleSafety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study.
Author(s)Shelef A, Barak Y, Berger U, Paleacu D, Tadger S, Plopsky I, Baruch Y.
Journal, Volume, IssueJ Alzheimers Dis. 2016;51(1):15-9. doi: 10.3233/JAD-150915.
Major outcome(s)Following aspects significantly decreased: Delusions, agitation/aggression, irritability, apathy, and sleep and caregiver distress
IndicationAlzheimer's diseaseAbstract

BACKGROUND: Tetrahydrocannabinol (THC) is a potential treatment for Alzheimer's disease (AD). OBJECTIVE: To measure efficacy and safety of medical cannabis oil (MCO) containing THC as an add-on to pharmacotherapy, in relieving behavioral and psychological symptoms of dementia (BPSD). METHODS: Eleven AD patients were recruited to an open label, 4 weeks, prospective trial. RESULTS: Ten patients completed the trial. Significant reduction in CGI severity score (6.5 to 5.7; p&#8202;< &#8202;0.01) and NPI score were recorded (44.4 to 12.8; p&#8202;< &#8202;0.01). NPI domains of significant decrease were: Delusions, agitation/aggression, irritability, apathy, sleep and caregiver distress. CONCLUSION: Adding MCO to AD patients' pharmacotherapy is safe and a promising treatment option.

Duration (days)28
ParticipantsTen patients with Alzheimer’s disease
DesignOpen study
Type of publicationMedical journal
Address of author(s)Abarbanel Mental Health Center, Bat-Yam, Israel and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Full text

[Back to Overview]  [IACM Homepage]